- PharmAust (PAA) is set to secure a European patent for the use of its Monepantel (MPL) product in combination with other drugs to treat cancer
- The company has been issued a “notice to grant” from the European Patent Office for pharmaceutical combinations of MPL and other anti-cancer drugs
- The patent will be published on March 8, with the company to soon receive a certificate of grant and the published patent specification
- The new patent extends PharmAust’s existing IP protection, which spans Australia, the US, China, Japan, Korea, Canada and New Zealand
- PharmAust shares are trading at 8 cents at 10:27 am AEDT
PharmAust (PAA) is set to receive a European patent for its use of Monepantel combinations in cancer.
The company was issued a “notice to grant” from the European Patent Office for pharmaceutical combinations of Monepantel (MPL) and other anti-cancer drugs.
Combination-drug therapy is widespread in cancer treatment, where the therapeutic regimen aims to minimise the possibility of drug resistance.
In PharmAust’s case, the patent coverage relates to mTOR pathway-interfering drugs and anticancer compounds for particular use in cancer treatment. mTOR pathway-interfering medicines aim to stop the signalling pathway in cells that help their growth and survival.
PharmAust has been trialling MPL and other drug combinations to interfere with this pathway as a potential way to treat cancer and neurodegenerative diseases.
The company has previously evaluated MPL in phase one clinical trials in humans and phase two clinical trials in dogs. The treatment was shown to be well-tolerated in humans, demonstrating preliminary evidence of anticancer activity, and objective anticancer activity in dogs.
The patent will be published on March 8, with the company to soon receive a certificate of grant and the published patent specification.
The new patent extends PharmAust’s existing protection, which spans Australia, the US, China, Japan, Korea, Canada and New Zealand.
PharmAust shares were trading at 8 cents at 10:27 am AEDT.